SLDB

Solid Biosciences Inc.

Price Chart

Latest Quote

$8.33

+1.02 (+13.95%)

Current Price

Previous Close	$7.31
Open	$7.58
Day High	$8.42
Day Low	$7.49
Volume	11,078,115

Fetched: 2026-06-20T06:34:35

Stock Information

Shares Outstanding	98.45M
Total Debt	$20.67M
Cash Equivalents	$380.68M
Net Income	$-191.78M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$820.09M
EPS (TTM)	$-1.92
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$336.02M
Income	$-191.78M
Book/sh	$3.80
Cash/sh	$3.87
Employees	121

Financial Ratios

Quick Ratio	12.57
Current Ratio	13.10
Debt/Eq	5.52

Returns & Margins

ROA	-32.03%
ROE	-57.37%

Ownership

Insider Ownership	0.74%
Institutional Ownership	101.68%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-4.26
P/B	2.19

Analyst Data

Recommendation	strong_buy
Target Price	$17.38

Technical Indicators

SMA20	$7.00
SMA50	$7.35
SMA200	$6.28
RSI	60.08
ATR	0.5454

Shares Float	53.74M
Short Float	11.22%
Short Ratio	8.12
Volatility	2.43
Rel Volume	7.48

Performance History

Week	+15.37%
Month	+37.01%
Quarter	+16.99%
6 Months	+43.13%
YTD	+52.84%
Year	+80.69%
3 Years	+34.79%
5 Years	-86.49%
10 Years	-97.54%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$8.33	14,768,100
2026-06-17	$7.31	3,405,200
2026-06-16	$7.07	1,288,400
2026-06-15	$7.36	2,064,000
2026-06-12	$7.14	1,664,600
2026-06-11	$7.22	2,902,700
2026-06-10	$6.61	1,137,300
2026-06-09	$6.57	957,700
2026-06-08	$6.41	862,800
2026-06-05	$6.70	701,800
2026-06-04	$7.24	1,009,100
2026-06-03	$6.85	998,500
2026-06-02	$6.58	1,581,700
2026-06-01	$7.19	771,000
2026-05-29	$7.34	1,268,100
2026-05-28	$7.07	727,900
2026-05-27	$7.02	868,100
2026-05-26	$6.88	790,800
2026-05-22	$6.62	967,900
2026-05-21	$6.50	742,800
2026-05-20	$6.47	1,059,400
2026-05-19	$6.08	1,831,700

About Solid Biosciences Inc.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

📰 Latest News

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires • 2026-06-18T15:04:44Z

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Insider Monkey • 2026-05-20T12:36:16Z

Solid Biosciences says interim results reinforce confidence in SGT-003 potential

TipRanks • 2026-03-12T17:10:35Z

Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks

Motley Fool • 2026-03-11T21:55:13Z

Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update

MarketBeat • 2026-02-15T10:35:20Z

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?

Zacks • 2026-01-16T14:08:00Z

JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success

Pharmaceutical Technology • 2026-01-15T17:58:13Z

Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy

Insider Monkey • 2025-12-16T04:10:42Z

Will Solid Biosciences (NASDAQ:SLDB) Spend Its Cash Wisely?

Simply Wall St. • 2025-10-24T12:56:11Z

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

Insider Monkey • 2025-07-29T13:35:42Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$8,094,000
Operating Revenue	$0	$0	$0	$8,094,000
Expenses
Total Expenses	$179,206,000	$129,728,000	$104,315,000	$107,368,000
Other Income Expense	$-5,226,000	$-4,098,000	$1,158,000	$10,677,000
Other Non Operating Income Expenses	$824,000	$652,000	$1,095,000	$-381,000
Net Non Operating Interest Income Expense	$10,107,000	$9,129,000	$7,142,000	$2,616,000
Operating Expense	$179,206,000	$129,728,000	$104,315,000	$107,368,000
General And Administrative Expense	$38,881,000	$33,297,000	$27,752,000	$28,948,000
Interest Expense	-	$340,000	$440,000	-
Interest Expense Non Operating	-	$340,000	$440,000	-
Total Other Finance Cost	-	-	-	$-2,616,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Net Interest Income	$10,107,000	$9,129,000	$7,142,000	$2,616,000
Interest Income	$10,107,000	$9,469,000	$7,582,000	$2,616,000
Normalized Income	$-168,275,000	$-119,947,000	$-96,078,000	$-97,039,000
Net Income From Continuing And Discontinued Operation	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Total Operating Income As Reported	$-179,206,000	$-129,728,000	$-104,252,000	$-106,452,000
Net Income Common Stockholders	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Net Income	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Net Income Including Noncontrolling Interests	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Net Income Continuous Operations	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Pretax Income	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Interest Income Non Operating	$10,107,000	$9,469,000	$7,582,000	$2,616,000
Operating Income	$-179,206,000	$-129,728,000	$-104,315,000	$-99,274,000
Special Income Charges	-	$0	$63,000	$11,058,000
Per Share
Diluted EPS	$-1.99	$-3.06	$-4.83	$-10.10
Basic EPS	$-1.99	$-3.06	$-4.83	$-10.10
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-171,520,000	$-117,152,000	$-93,057,000	$-107,924,000
Total Unusual Items	$-6,050,000	$-4,750,000	$63,000	$11,058,000
Total Unusual Items Excluding Goodwill	$-6,050,000	$-4,750,000	$63,000	$11,058,000
Reconciled Depreciation	$1,636,000	$2,455,000	$2,581,000	$2,408,000
EBITDA (Bullshit earnings)	$-177,570,000	$-121,902,000	$-92,994,000	$-96,866,000
EBIT	$-179,206,000	$-124,357,000	$-95,575,000	$-99,274,000
Diluted Average Shares	$87,504,631	$40,816,694	$19,884,007	$8,512,089
Basic Average Shares	$87,504,631	$40,816,694	$19,884,007	$8,512,089
Diluted NI Availto Com Stockholders	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Gain On Sale Of Security	$-6,050,000	$-4,750,000	-	-
Research And Development	$140,325,000	$96,431,000	$76,563,000	$78,420,000
Selling General And Administration	$38,881,000	$33,297,000	$27,752,000	$28,948,000
Other Gand A	$38,881,000	$33,297,000	$27,752,000	$28,948,000
Restructuring And Mergern Acquisition	-	$0	$-63,000	$-11,058,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Total Assets	$232,540,000	$188,662,000	$164,939,000	$260,252,000
Total Non Current Assets	$27,084,000	$31,360,000	$35,205,000	$40,614,000
Other Non Current Assets	$991,000	$2,318,000	$2,042,000	$2,008,000
Current Assets	$205,456,000	$157,302,000	$129,734,000	$219,638,000
Other Current Assets	$2,415,000	$1,651,000	$2,114,000	$3,003,000
Restricted Cash	$1,222,000	$0	-	-
Prepaid Assets	$13,969,000	$6,731,000	$3,980,000	$2,913,000
Cash Cash Equivalents And Short Term Investments	$187,850,000	$148,920,000	$123,640,000	$213,722,000
Cash And Cash Equivalents	$59,900,000	$80,235,000	$74,015,000	$155,384,000
Receivables	-	-	-	$0
Accounts Receivable	-	-	-	$0
Debt
Total Debt	$21,161,000	$24,177,000	$26,265,000	$28,547,000
Long Term Debt And Capital Lease Obligation	$19,058,000	$21,159,000	$23,941,000	$25,982,000
Current Debt And Capital Lease Obligation	$2,103,000	$3,018,000	$2,324,000	$2,565,000
Liabilities
Total Liabilities Net Minority Interest	$52,530,000	$51,416,000	$38,458,000	$48,586,000
Total Non Current Liabilities Net Minority Interest	$19,058,000	$21,159,000	$23,941,000	$26,078,000
Current Liabilities	$33,472,000	$30,257,000	$14,517,000	$22,508,000
Other Current Liabilities	$9,200,000	$3,150,000	$24,000	$14,000
Payables And Accrued Expenses	$13,354,000	$17,868,000	$6,245,000	$11,559,000
Payables	$3,224,000	$4,237,000	$2,032,000	$3,238,000
Accounts Payable	$3,224,000	$4,237,000	$2,032,000	$3,238,000
Other Non Current Liabilities	-	-	-	$96,000
Current Deferred Liabilities	-	-	-	$0
Equity
Common Stock Equity	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Total Equity Gross Minority Interest	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Stockholders Equity	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Gains Losses Not Affecting Retained Earnings	$52,000	$47,000	$15,000	$-68,000
Other Equity Adjustments	$52,000	$47,000	$15,000	$-68,000
Retained Earnings	$-957,775,000	$-783,450,000	$-658,753,000	$-562,738,000
Other
Ordinary Shares Number	$78,967,888	$40,468,141	$20,386,606	$19,556,732
Share Issued	$78,967,888	$40,468,141	$20,386,606	$19,556,732
Tangible Book Value	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Invested Capital	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Working Capital	$171,984,000	$127,045,000	$115,217,000	$197,130,000
Capital Lease Obligations	$21,161,000	$24,177,000	$26,265,000	$28,547,000
Total Capitalization	$180,010,000	$137,246,000	$126,481,000	$211,666,000
Additional Paid In Capital	$1,137,654,000	$920,609,000	$785,199,000	$774,452,000
Capital Stock	$79,000	$40,000	$20,000	$20,000
Common Stock	$79,000	$40,000	$20,000	$20,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$19,058,000	$21,159,000	$23,941,000	$25,982,000
Current Capital Lease Obligation	$2,103,000	$3,018,000	$2,324,000	$2,565,000
Pensionand Other Post Retirement Benefit Plans Current	$8,815,000	$6,221,000	$5,948,000	$8,370,000
Current Accrued Expenses	$10,130,000	$13,631,000	$4,213,000	$8,321,000
Net PPE	$26,093,000	$29,042,000	$33,163,000	$38,606,000
Accumulated Depreciation	$-14,190,000	$-13,026,000	$-12,735,000	$-10,956,000
Gross PPE	$40,283,000	$42,068,000	$45,898,000	$49,562,000
Leases	$483,000	$470,000	$481,000	$384,000
Construction In Progress	$397,000	$879,000	$410,000	$1,715,000
Other Properties	$37,550,000	$38,699,000	$42,676,000	$45,365,000
Machinery Furniture Equipment	$1,853,000	$2,020,000	$2,331,000	$2,098,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$127,950,000	$68,685,000	$49,625,000	$58,338,000
Treasury Shares Number	-	-	$0	-
Current Deferred Revenue	-	-	-	$0

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-157,442,000	$-100,666,000	$-95,695,000	$-100,992,000
Operating Activities
Operating Cash Flow	$-156,289,000	$-100,012,000	$-94,180,000	$-97,977,000
Cash Flow From Continuing Operating Activities	$-156,289,000	$-100,012,000	$-94,180,000	$-97,977,000
Operating Gains Losses	$6,050,000	$4,750,000	$374,000	-
Investing Activities
Capital Expenditure	$-1,153,000	$-654,000	$-1,515,000	$-3,015,000
Investing Cash Flow	$-58,454,000	$-16,086,000	$9,689,000	$59,157,000
Cash Flow From Continuing Investing Activities	$-58,454,000	$-16,086,000	$9,689,000	$59,157,000
Financing Activities
Repurchase Of Capital Stock	$-1,681,000	$-5,111,000	$0	-
Issuance Of Capital Stock	$196,419,000	$127,227,000	$2,974,000	$72,551,000
Financing Cash Flow	$194,446,000	$122,437,000	$3,122,000	$74,831,000
Cash Flow From Continuing Financing Activities	$194,446,000	$122,437,000	$3,122,000	$74,831,000
Net Common Stock Issuance	$194,738,000	$122,116,000	$2,974,000	$72,551,000
Common Stock Issuance	$196,419,000	$127,227,000	$2,974,000	$72,551,000
Other
Repayment Of Debt	$-723,000	$-473,000	$0	$-66,000
End Cash Position	$61,890,000	$82,187,000	$75,848,000	$157,217,000
Beginning Cash Position	$82,187,000	$75,848,000	$157,217,000	$121,206,000
Changes In Cash	$-20,297,000	$6,339,000	$-81,369,000	$36,011,000
Proceeds From Stock Option Exercised	$431,000	$794,000	$148,000	$203,000
Common Stock Payments	$-1,681,000	$-5,111,000	$0	-
Net Issuance Payments Of Debt	$-723,000	$-473,000	$0	$2,077,000
Net Long Term Debt Issuance	$-723,000	$-473,000	$0	$2,077,000
Long Term Debt Payments	$-723,000	$-473,000	$0	$-66,000
Net Investment Purchase And Sale	$-57,386,000	$-15,437,000	$11,204,000	$30,049,000
Sale Of Investment	$178,500,000	$188,900,000	$128,632,000	$212,811,000
Purchase Of Investment	$-235,886,000	$-204,337,000	$-117,428,000	$-182,762,000
Net PPE Purchase And Sale	$-1,068,000	$-649,000	$-1,515,000	$-2,415,000
Sale Of PPE	$85,000	$5,000	$0	$600,000
Purchase Of PPE	$-1,153,000	$-654,000	$-1,515,000	$-3,015,000
Change In Working Capital	$-6,822,000	$2,850,000	$-8,868,000	$-3,689,000
Change In Other Current Liabilities	$-1,786,000	$-1,676,000	$-1,735,000	-
Change In Payables And Accrued Expense	$2,957,000	$6,971,000	$-7,731,000	$586,000
Change In Accrued Expense	$4,050,000	$4,766,000	$-6,967,000	$5,832,000
Change In Payable	$-1,093,000	$2,205,000	$-764,000	$-5,246,000
Change In Account Payable	$-1,093,000	$2,205,000	$-764,000	$-5,246,000
Change In Prepaid Assets	$-7,993,000	$-2,445,000	$598,000	$3,695,000
Other Non Cash Items	$2,132,000	$7,703,000	$2,905,000	$-18,485,000
Stock Based Compensation	$16,914,000	$10,519,000	$7,625,000	$7,537,000
Amortization Of Securities	$-1,874,000	$-3,592,000	$-2,408,000	$233,000
Depreciation Amortization Depletion	$1,636,000	$2,455,000	$2,581,000	$2,408,000
Depreciation And Amortization	$1,636,000	$2,455,000	$2,581,000	$2,408,000
Depreciation	$1,636,000	$2,455,000	$2,581,000	$2,408,000
Gain Loss On Investment Securities	$6,050,000	$4,750,000	-	-
Net Income From Continuing Operations	$-174,325,000	$-124,697,000	$-96,015,000	$-85,981,000
Issuance Of Debt	-	-	$0	$2,143,000
Long Term Debt Issuance	-	-	$0	$2,143,000
Net Business Purchase And Sale	-	-	$0	$31,523,000
Sale Of Business	-	-	$0	$31,523,000
Change In Receivables	-	-	$0	$110,000
Changes In Account Receivables	-	-	$0	$110,000
Gain Loss On Sale Of PPE	-	-	$374,000	$0
Change In Other Working Capital	-	-	-	$-8,080,000

Fetched: 2026-06-16